170 related articles for article (PubMed ID: 35293763)
21. Differential Expression of CKLF-like MARVEL Transmembrane Domain-Containing Protein 6 and Programmed Cell Death Ligand 1 as Prognostic Biomarkers in Upper Tract Urothelial Carcinoma.
Kdimati S; Christoph C; Glass Ä; Engel N; Dräger DL; Maletzki C; Becker AS; Zimpfer A
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542462
[TBL] [Abstract][Full Text] [Related]
22. RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1.
Burren S; Reche K; Blank A; Galvàn JA; Dawson H; Berger MD; Zlobec I; Lugli A
Pathol Res Pract; 2021 Jul; 223():153486. PubMed ID: 34051513
[TBL] [Abstract][Full Text] [Related]
23. Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer.
Zhang C; Zhao S; Wang X
Cancer Cell Int; 2021 Jan; 21(1):78. PubMed ID: 33509216
[TBL] [Abstract][Full Text] [Related]
24. The clinicopathological features of programmed death ligand-1 expression in colorectal carcinoma.
Al-Jussani GN; Alsughayer A; Yousuf MS; Mullahuwash Y; Dabbagh T; Sughayer MA
Int J Biol Markers; 2022 Sep; 37(3):322-327. PubMed ID: 35635229
[TBL] [Abstract][Full Text] [Related]
25. CMTM6 recruits T cells within the endocervical adenocarcinoma microenvironment and suppresses cell proliferation via the p53 pathway.
Liang HY; Chen SL; Cai SH; Zhang SW; Yang X; Wei LJ; Luo RZ; Liu LL
J Med Virol; 2023 Mar; 95(3):e28605. PubMed ID: 36815510
[TBL] [Abstract][Full Text] [Related]
26. Impact of sidedness of colorectal cancer on tumor immunity.
Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M
PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001
[TBL] [Abstract][Full Text] [Related]
27. Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma.
Liu LL; Zhang SW; Chao X; Wang CH; Yang X; Zhang XK; Wen YL; Yun JP; Luo RZ
Cancer Immunol Immunother; 2021 Feb; 70(2):417-429. PubMed ID: 32770259
[TBL] [Abstract][Full Text] [Related]
28. Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer.
Yang L; Liu S; He W; Xiong Z; Xia L
BMC Cancer; 2023 Mar; 23(1):221. PubMed ID: 36894899
[TBL] [Abstract][Full Text] [Related]
29. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.
Zugazagoitia J; Liu Y; Toki M; McGuire J; Ahmed FS; Henick BS; Gupta R; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
J Thorac Oncol; 2019 Dec; 14(12):2084-2096. PubMed ID: 31605795
[TBL] [Abstract][Full Text] [Related]
30. CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma.
Zhang S; Yan Q; Wei S; Feng X; Xue M; Liu L; Cui J; Zhang Y
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Aug; 132(2):202-209. PubMed ID: 34034998
[TBL] [Abstract][Full Text] [Related]
31. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma.
Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Morinaga A; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
Hepatol Commun; 2021 Feb; 5(2):334-348. PubMed ID: 33553979
[TBL] [Abstract][Full Text] [Related]
32. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
Ishihara S; Iwasaki T; Kohashi K; Yamada Y; Toda Y; Ito Y; Susuki Y; Kawaguchi K; Takamatsu D; Kawatoko S; Kiyozawa D; Mori T; Kinoshita I; Yamamoto H; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2003-2011. PubMed ID: 33811537
[TBL] [Abstract][Full Text] [Related]
33. B7-H3 and PD-L1 Expression Are Prognostic Biomarkers in a Multi-racial Cohort of Patients with Colorectal Cancer.
Zhang W; Acuna-Villaorduna A; Kuan K; Gupta S; Hu S; Ohaegbulam K; Albanese J; Kaumaya M; Levy R; Hwang RR; Zang X; Lin J; Liu Q; Maitra R; Goel S
Clin Colorectal Cancer; 2021 Jun; 20(2):161-169. PubMed ID: 33745842
[TBL] [Abstract][Full Text] [Related]
34. Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer.
Wangefjord S; Brändstedt J; Lindquist KE; Nodin B; Jirström K; Eberhard J
Diagn Pathol; 2013 Jan; 8():10. PubMed ID: 23337059
[TBL] [Abstract][Full Text] [Related]
35. [Expression of immune checkpoints PD-L1, CTLA4, LAG3 in the microenvironment of colon adenocarcinoma depending on MMR status].
Naumov SS; Krakhmal NV; Tashireva LA; Vtorushin SV
Arkh Patol; 2024; 86(2):6-13. PubMed ID: 38591901
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.
Kawazoe A; Shitara K; Kuboki Y; Bando H; Kojima T; Yoshino T; Ohtsu A; Ochiai A; Togashi Y; Nishikawa H; Doi T; Kuwata T
Gastric Cancer; 2019 Jan; 22(1):69-76. PubMed ID: 29859006
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathological significance of PD-L1 expression in colorectal cancer: Impact of PD-L1 expression on pFOXO1 expression.
Pyo JS; Ko SH; Ko YS; Kim NY
Pathol Res Pract; 2020 Feb; 216(2):152764. PubMed ID: 31836325
[TBL] [Abstract][Full Text] [Related]
38. Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy.
Dunne PD; McArt DG; O'Reilly PG; Coleman HG; Allen WL; Loughrey M; Van Schaeybroeck S; McDade S; Salto-Tellez M; Longley DB; Lawler M; Johnston PG
Cancer Immunol Res; 2016 Jul; 4(7):582-91. PubMed ID: 27197062
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of the wnt signalling pathway molecules APC, beta-catenin and E-cadherin in colorectal cancer: a tissue microarray-based analysis.
Lugli A; Zlobec I; Minoo P; Baker K; Tornillo L; Terracciano L; Jass JR
Histopathology; 2007 Mar; 50(4):453-64. PubMed ID: 17448021
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer.
Chen QY; Chen YX; Han QY; Zhang JG; Zhou WJ; Zhang X; Ye YH; Yan WH; Lin A
Front Immunol; 2021; 12():679090. PubMed ID: 34054869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
